Presentation is loading. Please wait.

Presentation is loading. Please wait.

Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases  Marc Riquet, MD, PhD, Patrick Bagan,

Published byMargareta Falk Modified over 5 years ago

Similar presentations

Presentation on theme: "Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases  Marc Riquet, MD, PhD, Patrick Bagan,"— Presentation transcript:

1 Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases  Marc Riquet, MD, PhD, Patrick Bagan, PMD, Françoise Le Pimpec Barthes, MD, Eugeniu Banu, MD, Florian Scotte, MD, Christophe Foucault, MD, Antoine Dujon, MD, Claire Danel, MD  The Annals of Thoracic Surgery  Volume 84, Issue 6, Pages (December 2007) DOI: /j.athoracsur Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Five-year and 10-year survival rates of single N2 patients (curve 1) and multiple N2 patients (curve 2). Survival difference were similar when postoperative and cancer-unrelated deaths were excluded: single N2 (n = 305), 32.2% (median, 28 months); multiple N2 (n = 167), 19% (median, 17 months; p = ) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Five-year survival rates according to the size of lymph nodes. Nonbulky N2 (curve 2) demonstrated the best prognosis with a 5-year overall survival of 34% (median, 28 months). Micrometastases (curve 1) and bulky metastases (curve 3) demonstrated similar 5-year survival rates: 21.4% (median, 23 months) and 23% (median, 23 months), respectively. Difference between curve 2 and 3 was significant (p = 0.026). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Five-year survival rates according to the size of lymph node metastases when cancer-unrelated causes of death (postoperative and known medical causes) were excluded. Differences between the three subgroups were not significant: 5-year overall survival (median) were 24.4% (24 months), 40.1% (35 months), and 26.1% (24 months), respectively; the difference between G2 and G3 was significant (p = 0.03). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Five-year survival rates when only one lymph node was metastatic within the station: survival of micrometastases group (curve 1, 5-year overall survival, 16.6%; median, 23 months) was poorer (p = 0.02), whereas significance between the nonbulky metastases (curve 2; 5-year, 32.5%; median, 30 months) and bulky (curve 3; 5-year, 27.6%; median 23 months) was not significant (p = 0.12). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "Completely Resected Non-Small Cell Lung Cancer: Reconsidering Prognostic Value and Significance of N2 Metastases  Marc Riquet, MD, PhD, Patrick Bagan,"

Similar presentations

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.
Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor  Marc Riquet, MD, PhD, Antoine Legras, MD,

Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor  Marc Riquet, MD, PhD, Antoine Legras, MD,
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.

Number of Lymph Nodes and Metastatic Lymph Node Ratio Are Associated With Survival in Lung Cancer  Chukwumere E. Nwogu, MD, Adrienne Groman, MA, Daniel.
History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer  Pierre-Benoit Pagès, MD, Pierre Mordant,

History of Multiple Previous Malignancies Should Not Be a Contraindication to the Surgical Resection of Lung Cancer  Pierre-Benoit Pagès, MD, Pierre Mordant,
Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,

Long-Term Survival of Patients With pN2 Lung Cancer According to the Pattern of Lymphatic Spread  Antoine Legras, MD, Pierre Mordant, MD, PhD, Alex Arame,
Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection  Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Is the Rate of Pneumonectomy Higher in Right Middle Lobe Lung Cancer Than in Other Right-Sided Locations?  Caroline Rivera, MD, Pierre Mordant, MD, PhD,

Is the Rate of Pneumonectomy Higher in Right Middle Lobe Lung Cancer Than in Other Right-Sided Locations?  Caroline Rivera, MD, Pierre Mordant, MD, PhD,
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.

Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor  Marc Riquet, MD, PhD, Antoine Legras, MD,

Number of Mediastinal Lymph Nodes in Non-Small Cell Lung Cancer: A Gaussian Curve, Not a Prognostic Factor  Marc Riquet, MD, PhD, Antoine Legras, MD,
Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer  Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.

Prognostic Factors Associated With Interventional Bronchoscopy in Lung Cancer  Nicolas Guibert, MD, Julien Mazieres, MD, PhD, Benoît Lepage, MD, Gavin.
Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.

Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma  Giulio Melloni, MD, Claudio.
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.
Non-Small Cell Lung Cancer Resection in Lymphoma Patients

Non-Small Cell Lung Cancer Resection in Lymphoma Patients

Similar presentations

Ads by Google